What Is Selank Studied For? Research Areas, Per the Literature

Selank is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician with questions about any health condition or compound. The question "what is Selank used for" is answered here only in the sense of what researchers have studied it for, in which species, and with what study design.

What Selank is, in the words of the literature

Selank is a synthetic peptide built on the tuftsin sequence. A 2017 review of tuftsin properties and analogs in Current Medicinal Chemistry placed Selank among the tuftsin derivatives designed to extend the parent peptide's stability and described the research interest in tuftsin analogs as spanning immunomodulatory and neurotropic activity (PMID 28745220). That review is a narrative synthesis rather than a clinical trial, so it describes a research field rather than demonstrating outcomes in patients.

Almost all of the primary evidence summarised below comes from rodents. Where a research area is commonly searched for but is not supported by the verified papers cited here, that gap is stated plainly rather than filled with inference.

Research areas at a glance

Anxiety, stress and adaptive behaviour

The largest single theme is behaviour under stress. A 2003 paper in Neuroscience and Behavioral Physiology examined Selank and short peptides of the tuftsin family in the regulation of adaptive behaviour in stress, framing these peptides as regulators of behavioural responses in stressed animals (PMID 14969422). The work sits in the animal literature and addresses behavioural regulation rather than diagnosis or treatment of a human anxiety disorder.

A 2017 experiment published in Behavioural Neurology tested the peptide alongside a benzodiazepine: researchers reported that Selank enhanced the effect of diazepam in reducing anxiety-like behaviour in rats held under unpredictable chronic mild stress conditions (PMID 28280289). That finding is a drug interaction observation in a rodent stress model, and the study did not involve human participants.

What this does and does not establish

Animal anxiety models measure behaviour such as exploration and avoidance in standardised tests. They are screening tools. A positive result in rats, including the combination result reported in the 2017 rat study (PMID 28280289), does not establish efficacy, dosing or safety for any human condition.

Alcohol-related behaviour and withdrawal models

Two animal studies in the verified set address alcohol. A 2016 report in Bulletin of Experimental Biology and Medicine described that Selank inhibited ethanol-induced hyperlocomotion and the manifestation of behavioural sensitization in DBA/2 mice (PMID 27878720). Behavioural sensitization is a laboratory marker used to probe neuroadaptation to repeated ethanol exposure in mice.

A 2014 study in the same journal evaluated the peptide during modelling of withdrawal syndrome in rats with stable alcoholic motivation and characterised Selank as a peptide anxiolytic in that context (PMID 24913576). Both reports are rodent studies; neither involved people with alcohol use disorder, and neither supports any claim about treatment of dependence in humans.

Opioid withdrawal models

A 2022 paper in Bulletin of Experimental Biology and Medicine studied Selank, described there as a peptide analog of tuftsin, and reported that it attenuated aversive signs of morphine withdrawal in rats (PMID 36322304). The model measures withdrawal-associated behaviours in rodents after morphine exposure. No human opioid withdrawal trial of Selank appears in the verified citation set on this page.

Antenatal hypoxia, brain activity and biogenic amines

Two related reports examined long-term consequences of oxygen deprivation before birth. A 2006 article in Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova described normalizing effects of Selank on integrative brain activity and biogenic amine level disorders caused by antenatal hypoxia (PMID 17385425). A 2008 paper in Neuroscience and Behavioral Physiology covered the same theme, reporting the use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats following antenatal hypoxia (PMID 18197389).

Both are rat studies in a developmental insult model. Biogenic amines in this context refers to neurotransmitters such as monoamines measured in brain tissue. These findings describe changes in laboratory measures in animals and are not evidence about cognition in healthy people or about any paediatric condition.

Parkinson-like lesion models

A 2017 report in Doklady Biological Sciences examined the peptides Semax and Selank and reported effects on the behaviour of rats with 6-OHDA induced Parkinson-like parkinsonism (PMID 28702721). The 6-OHDA lesion is a toxin-based rodent model used to mimic dopaminergic loss. The study assessed behaviour in lesioned rats, not clinical outcomes in people with Parkinson disease, and no human Parkinson trial of Selank is present in the verified set used here.

Brain networks and molecular systems analysis

A 2020 paper in Doklady Biological Sciences applied a functional connectomic approach to studying Selank and Semax effects, situating the two peptides within network-level analysis rather than a single behavioural endpoint (PMID 32342318). This is preclinical and analytical work. It is useful for generating mechanistic hypotheses, and it does not measure symptoms or clinical endpoints in patients.

At the chemistry level, the 2017 tuftsin review remains the general reference point for how Selank relates structurally to tuftsin and why analog design was pursued (PMID 28745220).

Peripheral tissue changes in chronically stressed animals

Two histology studies looked beyond the brain. A 2019 report in Bulletin of Experimental Biology and Medicine examined the effect of Selank on morphological parameters of rat liver during chronic foot-shock stress (PMID 31243679). A 2020 report in the same journal described morphological changes in the large intestine of rats subjected to chronic restraint stress and treated with Selank (PMID 32651826).

These are tissue-level animal studies in stress paradigms. They describe microscopic structure in rats and do not establish any gastrointestinal or hepatic indication in humans.

Areas where the evidence here is weak, preclinical only, or absent

• Human anxiety disorders: the verified papers on this page are animal studies, including the rat chronic mild stress experiment (PMID 28280289), so no human efficacy claim can be drawn from them.
• Cognition, memory or focus in healthy adults: no study in the cited set tested healthy human volunteers; the nearest work measured brain activity indices in rats after antenatal hypoxia (PMID 18197389).
• Depression, sleep or immune indications: these are not addressed by any primary study in the verified set; the only immunological framing is the general discussion of tuftsin analogs in a review (PMID 28745220).
• Addiction treatment in people: the alcohol and opioid work is rodent behaviour only (PMID 27878720, PMID 36322304).
• Long-term outcomes: none of the cited studies followed animals or people over long periods for durable outcomes, including the stress histology studies (PMID 32651826).

Adverse Events: What Studies Report

The verified papers summarised here were designed around behavioural and tissue endpoints rather than formal safety reporting. The closest relevant data come from histology: the 2019 study assessed liver morphology in rats under chronic foot-shock stress (PMID 31243679), and the 2020 study assessed large intestine morphology in rats under chronic restraint stress (PMID 32651826). Those are structural observations in animals, not a safety profile.

No human adverse event dataset, no pharmacovigilance series and no tolerability trial appears in the citation set used on this page. Absence of reported harm in a small set of rodent experiments is not the same as evidence of safety, and the general review of tuftsin analogs does not supply human safety data either (PMID 28745220).

How to weigh this literature

1. Check the species. Every primary finding above was observed in rats or mice, for example the DBA/2 mouse ethanol experiment (PMID 27878720).
2. Check the model. Chronic mild stress, foot-shock, restraint, 6-OHDA lesion and antenatal hypoxia are all artificial paradigms; the 6-OHDA work is explicitly a parkinsonism model (PMID 28702721).
3. Check the endpoint. Behavioural scores, tissue morphology and neurotransmitter measurements are intermediate endpoints, as in the antenatal hypoxia reports (PMID 17385425).
4. Check replication. Several themes rest on single reports from a small number of groups, such as the morphine withdrawal study (PMID 36322304).

Regulatory status and closing note

Selank is not approved by the FDA as a medicine for any condition. This page is not guidance. Peptides of this kind are generally handled in the United States as research chemicals for laboratory use, and a research-area summary like this one describes published experiments only. Readers interested in the underlying papers can follow each PubMed link above, and a broader background page is available at /learn/selank/.

References

• Tuftsin: Properties and Analogs (Current Medicinal Chemistry, 2017)
• Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress (Neuroscience and Behavioral Physiology, 2003)
• Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (Behavioural Neurology, 2017)
• Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice (Bulletin of Experimental Biology and Medicine, 2016)
• Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation (Bulletin of Experimental Biology and Medicine, 2014)
• Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats (Bulletin of Experimental Biology and Medicine, 2022)
• Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia (Neuroscience and Behavioral Physiology, 2008)
• Selank-induced normalizing effects on the integrative brain activity and biogenic amine level disorders due to antenatal hypoxia (Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova, 2006)
• Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism (Doklady Biological Sciences, 2017)
• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress (Bulletin of Experimental Biology and Medicine, 2019)
• Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank (Bulletin of Experimental Biology and Medicine, 2020)